SikanderAilawadhiMD

PubMed

• Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
  Majid Jaberi-Douraki, Xuan Xu, Danai Dima, Sikander Ailawadhi, Faiz Anwer
  Blood Cancer Journal. 2024-12-20
• Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration.
  Tyler B Sandahl, Scott A Soefje, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo
  JCO Oncology Practice. 2024-12-20
• 4 citations
  Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
  Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
  Blood. 2024-12-05

Journal Articles

• Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells  
  Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature

Abstracts/Posters

• Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Sociodemographic and Clinical Characteristics Associated with PatientÍs Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patie...
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
  Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Racial Disparities in Multiple Myeloma Care 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all